CLEARSIDE BIOMEDICAL

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

07 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

06 Nov 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

04 Nov 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

31 Oct 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

22 Oct 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

09 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

27 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

01 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China

29 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

22 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

11 Jul 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

27 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

12 Jun 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®

21 May 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 15:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

08 May 2024 15:15:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024

30 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

16 Apr 2024 06:05:00 By Nasdaq GlobeNewswire